You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Stem Cells for Treating Acute Stroke

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: 999

    ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Structure-guided optimization of an in vivo active small molecule antitubercular targeting KasA

    SBC: COLLABORATIONS PHARMACEUTICALS INC            Topic: NIAID

    Project Summary The continued spread of drug resistant Mycobacterium tuberculosisMtbinfections has rendered tuberculosisTBa global health pandemic and pressed home the urgent need for new drugsCompounds which inhibit essential components of the Mtb cell wall rapidly cause cell death and are represented clinically by isoniazidIf any drug combination is likely to reduce treatment duration and preven ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Structure guided rational engineering of novel DNA reagents.

    SBC: NEW ENGLAND BIOLABS, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Type II restriction enzymes (REases) are indispensible tools of modern medical research. It has long been a goal of REase manufacturers to be able to offer programmable specificity enzymes, where the sequence recognizedand resulting cutting activity can be precisely directed to any desired point in a DNA, as this will offer opportunity for improvement in many a ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Survey and Test Platform for Use in Underserved Populations

    SBC: ADVANCED MEDICAL ELECTRONICS CORP            Topic: NEI

    DESCRIPTION (provided by applicant): Advanced Medical Electronics Corp, in collaboration with the Johns Hopkins University School of Medicine, proposes to develop a hardware/software platform suitable for administering a variety of tests and survey instruments to underserved populations in settings that can range from living rooms to libraries, community centers to nursing homes, and from inner ci ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. System-independent quantitative cardiac CT perfusion

    SBC: BIOINVISION INC            Topic: NHLBI

    System independent quantitative cardiac CT perfusion Summary BioInVisionIncand Case Western Reserve University researchers will develop software for quantitative analysis of cardiac CT perfusionCCTPcreating an important tool for evaluation of cardiovascular diseaseWith this productcardiologists will be able to identify functional flow deficits in coronary artery territoriesWhen one combines functi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Targeted Epigenetic Therapy for Triple-Negative Breast Cancer

    SBC: PARKSIDE SCIENTIFIC INC.            Topic: 102

    DESCRIPTIONprovided by applicantTriple negative breast cancerTNBCis one of the most aggressive forms of human cancerand currently has no targeted therapyChemotherapy is the only available treatment for TNBC patientsbut is deleterious and not effective once tumor spreadsTNBC represents a major unmet medical needaboutof breast cancer incidenceswomen worldwide inare TNBCTNBC disproportionally affects ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Targeted LystaMab Therapy to Optimize Tissue Engineered Vascular Graft Performance

    SBC: LYST THERAPEUTICS LLC            Topic: NHLBI

    Project Description Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require surgical interventionComplications arising from the use of currently available prosthetic materials in the form of vascular graftspatchesor replaceme ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Targeted Polymer Micelles for Treatment of Metastatic Melanoma

    SBC: INTEZYNE TECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting bacteria, the innate response of the middle ear to infection, and host-pathogen interactions, using topical and transtympanic applications for the treatment of otitis media.

    SBC: EARNANO LLC            Topic: NICHD

    Otitis media is a world wide disease primarily affecting the pediatric population under the age ofyearsIt is the most common reason for pediatric care visits and antibiotic therapyOver prescription and poorcompliance have led to a reduced susceptibility of bacteria to antibiotics andconsequentiallyto recurrent and chronic ear diseasesClearlythere is a compelling need to investigate alternative the ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government